Retina

Atsena reported that, since enrollment opened in May 2026, it has already accrued approximately 10% of the pivotal cohort and expects the pace to accelerate as additional sites across North America and Europe are activated.

Belite Bio has completed its rolling NDA submission to the FDA for tinlarebant, a potential first approved treatment for Stargardt disease type 1.

Optical coherence tomography angiography found distinctive microvascular signatures in the retinal layers associated with various stages of decline in cognition.

Alkeus Pharmaceuticals has dosed the first participant in the phase 3 NORTHSTAR trial of oral gildeuretinol for Stargardt disease, a condition with no approved treatments.

Finding satisfaction in ocular research—considerations about AI and enhanced datasets.

Therini Bio begins a phase 1b DME trial of THN391, an intravitreal antibody targeting fibrin-driven retinal inflammation.

Transient vision loss may foreshadow stroke or heart events; study urges urgent 90-day evaluation and long-term cardiovascular monitoring.

Swiss regulator backs tinlarebant for Stargardt as DRAGON phase 3 shows slower retinal atrophy, bringing first treatment closer to patients.

Two leading retinal specialists break down MCO-010's 3-year efficacy and safety data, the significance of contralateral eye findings, and how this gene-agnostic optogenetic approach could fill a critical gap for patients with advanced inherited retinal degeneration who have limited treatment options.

Wireless brain implant taps visual cortex to deliver artificial sight, marking third successful surgery and recruiting volunteers for trials.

Single-shot optogenetic injection restores light sensitivity in advanced retinitis pigmentosa, delivering sustained vision gains for years with strong safety, expanding hope beyond gene-specific therapy.

Learn how IBD affects gut and beyond—risk factors, gender differences, eye complications, and treatment options to manage flares and protect vision.

Data presented at ARVO 2026 show that high-dose gene therapy boosts central retinal sensitivity in X-linked retinitis pigmentosa, with the phase 3 VISTA study fully enrolled.

Phase 2 and phase 3 results in diabetic macular edema and uveitic macular edema support intravitreal anti–IL-6 therapy

Interim 6-month results from Part B of the LIGHTHOUSE trial show structural and functional improvements consistent with earlier cohorts; pivotal Phase 3 enrollment now underway with BLA filing targeted for 2028.

ECG-synchronized Doppler holography provides repeatable measurements of the retinal blood flow

According to the company, the NDA submission is supported by data from the phase 3 DRAGON trial.

Phase 3 data show brolucizumab outperforms laser for PDR vision preservation, with fewer adverse events—while monitoring inflammation risk.

The decision lengthens the approved treatment period outlined in the prescribing information and may lessen the need to change therapies for patients who continue to show a lasting response.

Images showed that Parkinson’s disease is associated with a thicker photoreceptor nuclear layer and a thinner layer of photoreceptor processes.

The ongoing GARDian3 study is designed to assess whether a single subretinal administration of OCU410ST can slow structural disease progression in patients with ABCA4-associated retinopathy.

Kodiak Sciences has indicated plans to submit a biologics license application (BLA) to the US Food and Drug Administration.